Wednesday, October 14, 2015
MTS Health Investors, LLC (“MTS”), the New York-based healthcare private equity firm, announced today that it has successfully completed the sale of its portfolio company, DNA Diagnostics Center (“DDC” or the “Company”), to GHO Capital for $110 million.
DDC is a market leading diagnostics business and is one of the world’s largest providers of private DNA testing services. The Company’s platform technology offers a wide range of products in the fields of biological family relationship testing, veterinary services, forensic services and medical applications for the pharmaceutical industry including cell-line authentication. DDC currently processes over 750,000 tests per annum in its state-of-the-art facility and is consistently recognised as the laboratory of choice for high quality results and excellence in customer service.
DDC President and CEO, Peter Vitulli, said, “The exceptional support and commitment provided by MTS was instrumental to our success. Their partnership afforded us with the necessary resources to create a premier, global organization in the testing space that has become known for our best-in-class testing capabilities and reputation.”
“It has been exciting and rewarding to partner with the DDC management team as they have executed on their growth strategy over the past few years,” said MTS Managing Director Alex Buzik. “We are thankful for the opportunity to work with such high-caliber executives to cement DDC’s market leading position in the private DNA testing market and position the Company for continued success.”
Robert W. Baird & Co served as the financial advisor to DDC and MTS. Hogan Lovells provided legal counsel to DDC and MTS.
finance.yahoo.com
